Aim: To summarize data for cervical loop electrosurgical excision procedures (LEEP) in Israel from 2001 to 2007 inclusive. Methods: 16 colposcopy specialists in Israel completed yearly questionnaires that assessed their LEEP. Results: Of the 2,681 LEEP reported, cervical intraepithelial neoplasia 2/3 (CIN 2/3) and CIN 1 were the main indications, with 63.2 and 20.5%, respectively. CIN 2/3 was detected in 111 (20.4%) of those for whom CIN 1 was the indication for LEEP. Of those diagnosed with CIN 2/3 following LEEP, 34.8% (426/1,225) were in the 18- to 34-year age range. The agreement between punch and LEEP biopsies was 80.15% and the ĸ value was 0.536 (moderate agreement). Complications included severe bleeding in 3.02% during the procedure(s) and 2.99% in the 3 weeks following LEEP. Conclusions: In one-fifth of the women for whom CIN 1 was the indication for LEEP, CIN 2/3 was the final diagnosis. More than one-third of the cases of CIN 2/3 and carcinoma were diagnosed in women under the age of 35, the age at which Pap screening is offered in Israel. Based on these findings, the Israeli Society of Cervical Pathology and Colposcopy prepared guidelines for the treatment of CIN.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.